In-Vitro In-Vivo Protein Vaccine 
pharmaphorum
JANUARY 17, 2023
Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. At the end of last year, the UK government entered into a partnership with the company, which saw Moderna agree to provide 250 million vaccine doses per year over the course of a decade.
Drug Discovery World
FEBRUARY 1, 2024
From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. ELISA testing had shown that each patient—previously infected by SARS-CoV-2—now harboured antibodies that bound to various domains on the virus’ spike protein (S protein).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
JANUARY 14, 2024
With the increased interest and gradual shift of investment from small molecule drugs to biologics and the establishment of several biologics manufacturing companies / biologics CMOs, more than 250 biologic therapies and vaccines have been developed, globally. They are different from small molecules in terms of their size and complexity.
The Pharma Data
MARCH 25, 2022
People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld. People not adequately protected by a COVID-19 vaccine may particularly benefit from pre-exposure prophylaxis with Evusheld. 2-4 Evusheld was generally well-tolerated in the trial.(2-4).
Drug Discovery World
NOVEMBER 8, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.
Drug Discovery World
OCTOBER 13, 2022
However, as pharma sought solutions, the Emergency Use Authorization (EUA) of the Moderna and Pfizer-BioNTech vaccines emerged as the fastest, most efficient way to create a vaccination safe enough to inoculate over 11 billion patients 1,2. mRNA presents versatility plus flexibility to target a broader range of diseases. .
The Pharma Data
DECEMBER 9, 2020
With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? which will remain a key shareholder. SciNeuro Pharmaceuticals.
Expert insights. Personalized for you.
82 
Let's personalize your content